Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

2017452 citationsJournal Articlebronze Open Access

Authors

Good health and well-being

Published in: The Lancet

Volume 390, Issue 10101, pp. 1489-1498

Field-Weighted Citation Impact: 20.71